1
|
Heurteaux C, Guy N, Laigle C, Blondeau N, Duprat F, Mazzuca M, Lang-Lazdunski L, Widmann C, Zanzouri M, Romey G, Lazdunski M. TREK-1, a K+ channel involved in neuroprotection and general anesthesia. EMBO J 2004; 23:2684-95. [PMID: 15175651 PMCID: PMC449762 DOI: 10.1038/sj.emboj.7600234] [Citation(s) in RCA: 390] [Impact Index Per Article: 19.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2004] [Accepted: 04/19/2004] [Indexed: 12/13/2022] Open
Abstract
TREK-1 is a two-pore-domain background potassium channel expressed throughout the central nervous system. It is opened by polyunsaturated fatty acids and lysophospholipids. It is inhibited by neurotransmitters that produce an increase in intracellular cAMP and by those that activate the Gq protein pathway. TREK-1 is also activated by volatile anesthetics and has been suggested to be an important target in the action of these drugs. Using mice with a disrupted TREK-1 gene, we now show that TREK-1 has an important role in neuroprotection against epilepsy and brain and spinal chord ischemia. Trek1-/- mice display an increased sensitivity to ischemia and epilepsy. Neuroprotection by polyunsaturated fatty acids, which is impressive in Trek1+/+ mice, disappears in Trek1-/- mice indicating a central role of TREK-1 in this process. Trek1-/- mice are also resistant to anesthesia by volatile anesthetics. TREK-1 emerges as a potential innovative target for developing new therapeutic agents for neurology and anesthesiology.
Collapse
Affiliation(s)
- C Heurteaux
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - N Guy
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - C Laigle
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - N Blondeau
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - F Duprat
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - M Mazzuca
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - L Lang-Lazdunski
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - C Widmann
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - M Zanzouri
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - G Romey
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
| | - M Lazdunski
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Institut Paul Hamel, Sophia-Antipolis, Valbonne, France
- Institut de Pharmacologie Moléculaire et Cellulaire, CNRS-UMR 6097, Institut Paul Hamel, 660 Route des Lucioles, Sophia-Antipolis, 06560 Valbonne, France. Tel.: +33 493 957702/03; Fax: +33 493 957704; E-mail:
| |
Collapse
|